Skip to content

Johnson & Johnson's ACUVUE OASYS MAX Leads in Astigmatism Comfort, Expands to Multifocal Lenses

ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperforms rival in comfort and vision clarity. New multifocal lens brings daily disposable options to more astigmatic patients.

In the picture I can see a man is wearing spectacles. This picture is blurred.
In the picture I can see a man is wearing spectacles. This picture is blurred.

Johnson & Johnson's ACUVUE OASYS MAX Leads in Astigmatism Comfort, Expands to Multifocal Lenses

Johnson & Johnson has revealed new data that places its ACUVUE OASYS MAX 1-Day for ASTIGMATISM ahead of its competitor, Dailies Total1 for Astigmatism, in terms of patient preference and comfort. The company also announced an expansion in its product range to cater to a wider population of presbyopic patients.

In a recent study, 62% of patients chose ACUVUE OASYS MAX 1-Day for ASTIGMATISM over Dailies Total1 for Astigmatism for overall vision. This preference was echoed in other categories, with 65% preferring ACUVUE for vision on computer screens and digital devices, compared to just 16% for Dailies. Patients also consistently rated ACUVUE higher for overall opinion and all comfort metrics. Johnson & Johnson attributes these results to the superior design and materials of ACUVUE, which provide clearer vision and greater comfort throughout the day.

The company has also introduced ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and only daily disposable contact lens designed for patients with both astigmatism and presbyopia. This innovation broadens the range of patients who can benefit from daily disposable multifocal contact lenses, especially those with astigmatism. The lens is now available in the U.S., Canada, and select markets in the EMEA and APAC regions, with further launches planned.

Johnson & Johnson's ACUVUE OASYS MAX 1-Day for ASTIGMATISM has proven itself a preferred choice among patients for vision clarity and comfort. The company's expansion into multifocal lenses for astigmatic patients further demonstrates its commitment to improving sight for a wider range of people. These advancements, along with Johnson & Johnson's deep legacy in eye health, aim to benefit more than 40 million people each year.

Read also:

Latest